雜志介紹

Blood Cancer Journal雜志介紹

《Blood Cancer Journal》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱血癌雜志，本刊主要出版、報道醫(yī)學(xué)-HEMATOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗(yàn)和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為12.9，最新CiteScore 指數(shù)為16.7。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

  Author: Liu, Sining; Zhang, Xinyue; Dai, Haiping; Cui, Wei; Yin, Jia; Li, Zheng; Yang, Xiao; Yang, Chunxiu; Xue, Shengli; Qiu, Huiying; Miao, Miao; Chen, Suning; Jin, Zhengming; Fu, Chengcheng; Li, Caixia; Sun, Aining; Han, Yue; Wang, Ying; Yu, Lei; Wu, Depei; Cui, Qingya; Tang, Xiaowen

• Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

  Author: Zhang, Yinqiang; Li, Chenggong; Du, Mengyi; Jiang, Huiwen; Luo, Wenjing; Tang, Lu; Kang, Yun; Xu, Jia; Wu, Zhuolin; Wang, Xindi; Huang, Zhongpei; Zhang, Yanlei; Wu, Di; Chang, Alex H. H.; Hu, Yu; Mei, Heng

• High expression of PTPN21 in B-cell non-Hodgkin's gastric lymphoma, a positive mediator of STAT5 activity.

  Author: Plani-Lam JH, Chow TC, Fan YH, Garcia-Bloj B, Cheng L, Jin DY, Hancock W, Fanayan S, Ingley E, Song YQ.

• Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study.

  Author: Lu A, Fang Y, Du X, Li Y, Cai Z, Yu K, Zhao L, Wang B, Wu J, Cheng Y, Zuo Y, Jia Y, Tan F, Ding L, Lu J, Zhang L, Huang X.

英文介紹

Blood Cancer Journal雜志英文介紹

Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field.

Topics of particular interest include, but are not limited to, the following:

Preclinical studies of new compounds, especially those that provide mechanistic insights

Clinical trials and observations

Reviews related to new drugs and current management of hematologic malignancies

Novel observations related to new mutations, molecular pathways, and tumor genomics.